Research ArticleMetabolism, Transport, and Pharmacogenomics
CC-115, a dual mTOR/DNA-PK inhibitor in clinical trial, is a substrate of ABCG2, a risk factor for CC-115 resistance
Jenny Beebe and Jian-Ting Zhang
Journal of Pharmacology and Experimental Therapeutics August 27, 2019, jpet.119.258392; DOI: https://doi.org/10.1124/jpet.119.258392